INTRODUCTION {#s1}
============

The detection of multiple lesions of gastric cancer (GC) has been increasing along with advances in endoscopic and pathologic examinations. Synchronous multiple GCs (SMGC) have been reported to account for 5--15% of all GC cases \[[@R1]\]. However, accessory lesions are generally not considered as a prognostic factor in SMGC patients \[[@R2], [@R3]\].

GC patients sometimes present other primary malignancies (OPMs), particularly in the colon \[[@R4]\]. Recent studies have demonstrated an association between SMGC and OPMs, and found that this association was frequently observed in colorectal cancer patients \[[@R5], [@R6]\]. However, the exact relationship between SMGC and OPMs remains unclear, and it would be of clinical benefit to clarify what types of OPMs occur in SMGC patients.

With this in mind, we performed the present multi-center retrospective cohort study to clarify the relationship between SMGC and OPMs.

RESULTS {#s2}
=======

Patients {#s2_1}
--------

The characteristics of the study population are summarized in Figure [1](#F1){ref-type="fig"}. A total of 1121 consecutive patients with GC were treated surgically between 2002 and 2013 in Shinshu University Hospital, Shinshu Ueda Medical Center, and Nagano Prefectural Kiso Hospital. Excluding 17 patients with special types of histology, such as neuroendocrine carcinoma and squamous cell carcinoma, 1094 patients with gastric adenocarcinoma were enrolled in the present study. Of the 1094 patients with GC, 102 patients (9.3%) had SMGC, including 80 patients with 2 GCs, 18 patients with 3 GCs, and 1 patient each with 4, 5, 6, and 7 GCs. Fifty-five patients underwent gastrectomy after non-curative resection by endoscopic submucosal dissection (ESD), and 34 patients had GC in the remnant stomach. There was no patient with a new GC detected within 1 year after gastrectomy. Seventeen patients had metachronous GC, including 3 patients treated with endoscopic submucosal dissection and 14 patients treated with gastrectomy. Including these metachronous GCs, 115 patients had multiple GC (MGC); 4 patients had both SMGC and metachronous MGC. The mean follow up period was 41.8 months.

![Characteristics of the enrolled study patients\
A total of 1121 consecutive patients with gastric cancer (GC) were treated surgically between 2002 and 2013. After excluding 17 patients with special types of histology, 1094 patients with gastric adenocarcinoma were enrolled. Seventeen patients had metachronous GC. Including these metachronous GCs, 115 patients had multiple GCs (MGC). ^\*^Four patients had both synchronous MGC (SMGC) and metachronous MGC.](oncotarget-09-20605-g001){#F1}

Clinicopathological features of MGC {#s2_2}
-----------------------------------

The clinicopathological features of the patients with or without SMGC are shown in Table [1](#T1){ref-type="table"}. SMGC was significantly more frequently observed in elderly patients (*p* = 0.002) and in patients with current smoking (*p* = 0.032), differentiated adenocarcinoma (*p* \< 0.001), early cancer (*p* = 0.001), negative node metastasis (*p* = 0.035), negative distant metastasis (*p* = 0.015), and preoperative OPMs (*p* \< 0.001) compared to in their counterparts.

###### Characteristics of patients with or without synchronous multiple gastric cancer

  -------------------------------------------------------------------------------------------
  Variable                          With SMGC\             Without SMGC\          *p*-value
                                    patients (*n* = 102)   patients (*n* = 992)   
  --------------------------------- ---------------------- ---------------------- -----------
  Age (years old: mean ± SD)        73.2 ± 10.3            69.7 ± 11.1            0.002

  Sex                                                                             0.127

   male                             77 (75.5%)             676 (68.1%)            

   female                           25 (24.5%)             316 (31.9%)            

  Alcohol consumption (every day)                                                 0.275

   with                             35 (34.3%)             289 (29.1%)            

   without                          67 (65.7%)             703 (70.9%)            

  Current smoking                                                                 0.032

   with                             35 (34.3%)             244 (24.6%)            

   without                          67 (65.7%)             748 (75.4%)            

  Preoperative OPM                                                                \<0.001

   with                             33 (32.4%)             165 (16.6%)            

   without                          69 (67.6%)             827 (83.4%)            

  Tumor location                                                                  0.544

   upper-third                      27 (26.5%)             240 (24.2%)            

   middle-third                     35 (34.3%)             396 (39.9%)            

   lower-third                      40 (39.2%)             356 (35.9%)            

  Tumor size (mm: mean ± SD)        40.9 ± 26.1            48.6 ± 33.4            0.057

  Histologic type                                                                 \<0.001

   differentiated (tub/pap)         77 (75.5%)             551 (55.5%)            

   undifferentiated (por/sig/muc)   25 (24.5%)             441 (44.5%)            

  Depth of invasion                                                               0.001

   pT1                              67 (65.7%)             474 (47.8%)            

   pT2 or more                      35 (34.3%)             518 (52.2%)            

  Node metastasis                                                                 0.035

   pN0                              71 (69.6%)             584 (58.9%)            

   pN1or more                       31 (30.4%)             408 (41.1%)            

  TNM Stage                                                                       \<0.001

   I                                74 (72.5%)             528 (53.2%)            

   II                               17 (16.7%)             164 (16.5%)            

   III                              9 (8.8%)               203 (20.5%)            

   IV                               2 (2.0%)               97 (9.8%)              

  Chemotherapy for gastric cancer                                                 

   with                             26 (25.5%)             347 (35.0%)            0.054

   without                          76 (74.5%)             645 (65.0%)            

  BMI (kg/m^2^: mean ± SD)          22.6 ± 4.2             22.2 ± 3.3             0.618

  Diabetes melites                                                                0.465

   with                             17 (16.7%)             139 (14.0%)            

   without                          85 (8.3%)              853 (86.0%)            
  -------------------------------------------------------------------------------------------

SMGC, synchronous multiple gastric cancer; SD, standerd deviation; OPM, other primary malignancy; tub, tubular adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma; muc, mucinous carcinoma; BMI, body mass index.

The clinicopathological features of the patients with or without MGC are shown in Table [2](#T2){ref-type="table"}. Similar to SMGC, MGC was significantly more frequently observed in elderly patients (*p* = 0.001), men (*p* = 0.036), and in patients with current smoking (*p* = 0.0499), differentiated adenocarcinoma (*p* \< 0.001), early cancer (*p* = 0.028), negative node metastasis (*p* = 0.025), and OPMs, including both synchronous and metachronous OPMs (*p* \< 0.001), than in patients without these factors.

###### Characteristics of patients with solitary and multiple gastric cancer

  -------------------------------------------------------------------------------------------
  Variable                          With MGC\              Without MGC\           *p*-value
                                    patients (*n* = 115)   patients (*n* = 979)   
  --------------------------------- ---------------------- ---------------------- -----------
  Age (years old: mean ± SD)        73.3 ± 10.2            69.6 ± 11.1            0.001

  Sex                                                                             0.036

   male                             89 (77.4%)             664 (67.8%)            

   female                           26 (22.6%)             315 (32.2%)            

  Alcohol consumption (every day)                                                 0.675

   with                             36 (31.3%)             288 (29.4%)            

   without                          79 (68.7%)             691 (70.6%)            

  Current smoking                                                                 0.0499

   with                             38 (33.0%)             241 (24.6%)            

   without                          77 (67.0%)             738 (75.4%)            

  OPM^\*^                                                                         \<0.001

   with                             43 (37.4%)             192 (19.6%)            

   without                          72 (62.6%)             787 (80.4%)            

  Tumor location                                                                  0.058

   upper-third                      38 (33.0%)             229 (23.4%)            

   middle-third                     37 (32.2%)             394 (40.2%)            

   lower-third                      40 (34.8%)             356 (36.4%)            

  Tumor size (mm: mean ± SD)        43.8 ± 29.0            48.33 ± 33.3           0.161

  Histologic type                                                                 \<0.001

   differentiated (tub/pap)         84 (73.0%)             544 (55.6%)            

   undifferentiated (por/sig/muc)   31 (27.0%)             435 (44.4%)            

  Depth of invasion                                                               0.028

   pT1                              47 (40.9%)             506 (51.7%)            

   pT2 or more                      68 (59.1%)             473 (48.3%)            

  Node metastasis                                                                 0.025

   pN0                              80 (69.6%)             575 (58.7%)            

   pN1or more                       35 (30.4%)             404 (41.3%)            

  TNM Stage                                                                       0.001

   I                                81 (70.4%)             521 (53.2%)            

   II                               19 (16.5%)             162 (16.5%)            

   III                              12 (10.4%)             200 (20.4%)            

   IV                               3 (2.6%)               96 (9.8%)              

  Chemotherapy for gastric cancer                                                 0.056

   with                             30 (26.1%)             343 (35.0%)            

   without                          85 (73.9%)             636 (65.0%)            

  BMI (kg/m^2^: mean ± SD)          22.3 ± 4.2             22.2 ± 3.3             0.835

  Diabetes melites                                                                0.463

   with                             19 (16.5%)             137 (14.0%)            

   without                          96 (83.5%)             842 (86.0%)            
  -------------------------------------------------------------------------------------------

MGC, multiple gastric cancer; SD, standerd deviation; OPM, other primary malignancy; tub, tubular adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma; muc, mucinous carcinoma; BMI, body mass index.

^\*^OPM include pre- and postoperative cancers.

Occurrence of OPMs during the pre- and postoperative period {#s2_3}
-----------------------------------------------------------

The most frequently observed malignancy in the total cohort was colorectal cancer, which was observed in 77 patients, followed by prostate and lung cancers. Malignancies of the thyroid (*p* = 0.031), esophagus (*p* = 0.044), and colorectum (*p* = 0.025) were more frequently observed in patients with SMGC than in those without (Table [3](#T3){ref-type="table"}).

###### Solitary and synchronous multiple gastric cancer patients with other primary malignancies including pre- and postoperatively diagnosed

  ------------------------------------------------------------------------------------
  OPM\                       With SMGC\             Without SMGC\          *p*-value
  (pre- and postoperative)   patients (*n* = 102)   patients (*n* = 992)   
  -------------------------- ---------------------- ---------------------- -----------
  Brain                      1 (1.0%)               0 (0%)                 0.093

  Head and neck                                                            

   Oral                      1 (1.0%)               0 (0%)                 0.093

   Laryngopharynx            0 (0%)                 12 (1.2%)              0.617

   Thyroid                   3 (2.9%)               5 (0.5%)               0.031

  Chest                                                                    

   Lung                      5 (4.9%)               23 (2.3%)              0.174

   Breast                    0 (0%)                 13 (1.3%)              0.624

  Gastrointestinal tract                                                   

   Esophagus                 4 (3.9%)               11 (1.1%)              0.043

   Colorectum                13 (12.7%)             64 (6.5%)              0.025

  Hepatobiliary system                                                     

   Liver                     1 (1.0%)               13 (1.3%)              1.000

   Bile duct                 0 (0%)                 4 (0.4%)               1.000

   Pancreas                  0 (0%)                 2 (0.2%)               1.000

  Urogenital system                                                        

   Kidney                    2 (2.0%)               4 (0.4%)               0.101

   Bladder                   2 (2.0%)               14 (1.4%)              0.655

   Prostate                  5 (4.9%)               25 (2.5%)              0.190

   Testis                    0 (0%)                 2 (0.2%)               1.000

  Gynecologic organs                                                       

   Uterus                    0 (0%)                 7 (0.7%)               1.000

   Ovary                     0 (0%)                 2 (0.2%)               1.000

  Retroperitoneum            1 (1.0%)               0 (0%)                 0.093

  Skin                       1 (1.0%)               4 (0.4%)               0.388

  Hematopoietic system       3 (2.9%)               11 (1.1%)              0.135

  Soft tissue                1 (1.0%)               1 (0.1%)               0.178

  Unknown origin             1 (1.0%)               0 (0%)                 0.093

  Total                      41 (40.2%)             194 (19.6%)            \<0.001
  ------------------------------------------------------------------------------------

OPM, other primary cancer; SMGC, synchronous multiple gastric cancer.

Both antecedent and synchronous OPMs were more frequently observed in patients with SMGC (*p* = 0.032 and 0.006, respectively; Table [4](#T4){ref-type="table"}). During the follow-up period, 9 OPMs were detected in 9 patients (8.8%) with SMGC, whereas 38 OPMs were detected in 37 patients (3.7%) without SMGC (*p* = 0.031; Table [4](#T4){ref-type="table"}). There was no case of OPM detected within 1 year after gastrectomy.

###### Other primary malignancies in patients with or without synchronous multiple gastric cancer

  ---------------------------------------------------------------------------
  Variable          With SMGC\             Without SMGC\          *p*-value
                    patients (*n* = 102)   patients (*n* = 992)   
  ----------------- ---------------------- ---------------------- -----------
  Antecedant OPM                                                  0.032

   with             16 (15.7%)             90 (9.1%)              

   without          86 (84.3%)             902 (90.1%)            

  Synchronous OPM                                                 0.006

   with             17 (16.7%)             84 (8.5%)              

   without          85 (83.3%)             908 (91.5%)            

  Subsequent OPM                                                  0.031

   with             9 (8.8%)               37 (3.7%)              

   without          93 (91.2%)             955 (96.3%)            
  ---------------------------------------------------------------------------

SMGC, synchronous multiple gastric cancer; OPM, other primary malignancy.

Relationships between MGC and OPMs {#s2_4}
----------------------------------

The presence of a preoperative OPM was found to be an independent risk factor for SMGC (*p* = 0.001; hazard ratio \[HR\]: 2.145, 95% confidence interval \[CI\]: 1.353--3.399; Table [5](#T5){ref-type="table"}), and the detection of an OPM either preoperatively or postoperatively was an independent risk factor for MGC (*p* \< 0.001; HR: 2.146, 95% CI: 1.409--3.268; Table [6](#T6){ref-type="table"}). Furthermore, patients with current smoking and with SMGC frequently developed OPMs postoperatively (Table [7](#T7){ref-type="table"}), and the presence of SMGC was demonstrated to be an independent risk factor for postoperative OPMs (*p* = 0.028; HR: 2.35, 95% CI: 1.095--5.045; Table [8](#T8){ref-type="table"}).

###### Multivariate analysis for risk factors of synchronous multiple gastric cancer

  Variable                             *p*-value   Hazard ratio   95% CI
  ------------------------------------ ----------- -------------- --------------
  Age (year)                           0.002       1.038          1.013--1.063
  Current smoking (with)               0.012       1.816          1.139--2.895
  Preoperative OPM (with)              0.001       2.145          1.354--3.399
  Histologic type (undifferentiated)   0.043       0.601          0.366--0.985
  Depth of invasion (pT2 or more)      0.793       0.92           0.494--1.713
  Node metastasis (pN1 or more)        0.065       1.794          0.965--3.335
  Stage (I, II, III, IV)               0.004       0.503          0.316--0.802

CI, confidence interval; OPM, other primary malignancy.

###### Multivariate analysis for risk factors of multiple gastric cancer

  Variable                             *p*-value   Hazard ratio   95% CI
  ------------------------------------ ----------- -------------- --------------
  Age (year)                           \<0.001     1.039          1.015--1.063
  Sex (male)                           0.001       1.314          0.801--2.157
  Current smoking (with)               0.062       1.553          0.978--2.465
  Pre- and postoperative OPM (with)    \<0.001     2.146          1.409--3.268
  Histologic type (undifferentiated)   0.106       0.683          0.430--1.085
  Depth of invasion (pT2 or more)      0.284       1.373          0.769--2.453
  Node metastasis (pN1 or more)        0.193       1.503          0.814--2.777
  Stage (I, II, III, IV)               0.004       0.47           0.282--0.783

CI, confidence interval; OPM, other primary malignancy.

###### Characteristics of patients with and without postoperative other primary malignancies

  --------------------------------------------------------------------------------------------
  Variable                          With postoperative\   Without postoperative\   *p*-value
                                    OPM (*n* = 46)        OPM (*n* = 1048)         
  --------------------------------- --------------------- ------------------------ -----------
  Age (years old: mean ± SD)        69.0 ± 7.9            70.1 ± 11.1              0.524

  Sex                                                                              0.158

   male                             36 (78.3%)            717 (68.4%)              

   female                           10 (21.7%)            331 (31.6%)              

  Alcohol consumption (every day)                                                  0.433

   with                             16 (34.8%)            308 (29.4%)              

   without                          30 (65.2%)            740 (70.6%)              

  Current smoking                                                                  0.030

   with                             18 (39.1%)            261 (24.9%)              

   without                          28 (60.9%)            787 (75.1%)              

  SMGC                                                                             0.032

   with                             9 (19.6%)             93 (8.9%)                

   without                          37 (80.4%)            955 (91.1%)              

  Tumor location                                                                   0.705

   upper-third                      12 (26.1%)            255 (24.3%)              

   middle-third                     20 (43.5%)            411 (39.2%)              

   lower-third                      14 (30.4%)            382 (36.5%)              

  Tumor size (mm: mean ± SD)        42.9 ± 29.1           48.06 ± 33.0             0.297

  Histologic type                                                                  0.902

   differentiated (tub/pap)         26 (56.5%)            602 (57.4%)              

   undifferentiated (por/sig/muc)   20 (43.5%)            446 (42.6%)              

  Depth of invasion                                                                0.939

   pT1                              23 (50.0%)            518 (49.4%)              

   pT2 or more                      23 (50.0%)            530 (50.6%)              

  Node metastasis                                                                  0.654

   pN0                              29 (63.0%)            626 (59.7%)              

   pN1or more                       17 (37.0%)            422 (40.3%)              

  TNM Stage                                                                        0.057

   I                                27 (58.7%)            575 (54.9%)              

   II                               12 (26.1%)            169 (16.1%)              

   III                              7 (15.2%)             205 (19.6%)              

   IV                               0 (0.0%)              99 (9.4%)                

  Chemotherapy for gastric cancer                                                  0.242

   with                             12 (26.1%)            361 (34.4%)              

   without                          34 (73.9%)            687 (65.6%)              

  BMI (kg/m^2^: mean ± SD)          22.0 ± 3.0            22.3 ± 3.4               0.646

  Diabetes melites                                                                 0.535

   with                             8 (17.4%)             148 (14.1%)              

   without                          38 (82.6%)            900 (85.9%)              
  --------------------------------------------------------------------------------------------

SMGC, synchronous multiple gastric cancer; SD, standerd deviation; OPM, other primary malignancy; tub, tubular adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma; muc, mucinous carcinoma; BMI, body mass index.

###### Multivariate analysis for risk factors of postoperative other primary malignancies

  Variable                 *p*-value   Hazard ratio   95% CI
  ------------------------ ----------- -------------- --------------
  Current smoking (with)   0.049       1.851          1.004--3.415
  SMGC (with)              0.028       2.35           1.095--5.045

CI, confidence interval; SMGC, synchronous multiple gastric cancer.

Clinical outcomes after surgery {#s2_5}
-------------------------------

There were 995 patients undergoing gastrectomy with curative intent for GC. In these patients, there were no differences in the overall survival (OS) or disease-specific survival (DSS) between the patients with (*n* = 100) and without SMGC (*n* = 895: Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}), or between patients with or without OPMs (Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). However, a significantly worse OS was observed in patients with preoperative OPMs than in those without (Figure [4A](#F4){ref-type="fig"}), whereas there was no difference in DSS (Figure [4B](#F4){ref-type="fig"}). In the multivariate analysis, although the presence of SMGC was not a significant predictive factor, preoperative OPM was identified as an independent prognostic factor in patients who underwent gastrectomy with curative intent (*p* = 0.021; HR: 1.481, 95% CI: 1.060--2.070; Table [9](#T9){ref-type="table"}).

![Survival curves of patients undergoing gastrectomy with curative intent according to the presence of synchronous multiple gastric cancers (SMGC)\
(**A**) Overall survival. No difference in overall survival was seen between patients with and without SMGC (*p* = 0.761). (**B**) Disease-specific survival. No difference in disease-specific survival was seen between patients with and without SMGC (*p* = 0.118).](oncotarget-09-20605-g002){#F2}

![Survival curves in patients undergoing gastrectomy with curative intent according to the presence of other primary malignancies (OPMs)\
(**A**) Overall survival. No difference in overall survival was seen between patients with and without OPMs (*p* = 0.064). (**B**) Disease-specific survival. No difference in disease-specific survival was seen between patients with and without OPMs (*p* = 0.076).](oncotarget-09-20605-g003){#F3}

![Survival curves in patients undergoing gastrectomy with curative intent according to the presence of other primary malignancies (OPMs) preoperatively\
(**A**) Overall survival. Patients with preoperative OPMs showed worse overall survival than those without (*p* = 0.033). (**B**) Disease-specific survival. No difference in disease-specific survival was seen between patients with and without preoperative OPMs (*p* = 0.647).](oncotarget-09-20605-g004){#F4}

###### Univariate and multivariate analysis on overall survival in gastrectomized patients with curative intent

  Variable                             Univariate analysis   Multivariate analysis                                    
  ------------------------------------ --------------------- ----------------------- -------------- --------- ------- --------------
  Age (year)                           \<0.001               1.05                    1.034--1.066   \<0.001   1.04    1.024--1.055
  Sex (male)                           0.053                 1.367                   0.996--1.878                     
  BMI (kg/m^2^)                        0.001                 0.93                    0.890--0.972   0.104     0.964   0.923--1.008
  SMGC (with)                          0.761                 0.928                   0.571--1.506                     
  Preoperative OPM (with)              0.035                 1.426                   1.026--1.983   0.021     1.481   1.060--2.070
  Histologic type (undifferentiated)   0.093                 1.266                   0.960--1.666                     
  Tumor size (mm)                      \<0.001               1.015                   1.011--1.018   0.005     1.007   1.002--1.012
  Tumor depth (pT2 or more)            \<0.001               3.586                   2.640--4.872   \<0.001   1.964   1.368--2.820
  Node metastasis (pN1 or more)        \<0.001               3.529                   2.662--4.680   \<0.001   2.03    1.455--2.831

CI, confidence interval; BMI, body mass index; SMGC, synchronous multiple gastric cancer; OPM, other primary malignancy.

DISCUSSION {#s3}
==========

Despite great efforts of gastrointestinal endoscopists to detect second or third lesions of GC, it is difficult to avoid missing lesions in cases of SMGC \[[@R7]\]. Various function-preserving procedures, such as endoscopic resection and limited gastrectomy, are performed for the treatment of GC \[[@R8]\]. However, these procedures lead to a larger remaining area of gastric mucosa with malignant potential in GC patients. Previous reports have demonstrated that SMGC are observed in 4--10% of GC patients \[[@R1], [@R7], [@R9]\], and the present study also showed a similar proportion. There are several risk factors for SMGC, such as advanced age, differentiated histology, and early GC \[[@R1]\]. Accordingly, in the present study, these factors were identified as independent risk factors of SMGC, consistent with previous studies.

Previous studies have reported an incidence of OPMs of 2.6--4.7% in GC patients \[[@R10]--[@R12]\]. Green *et al.* \[[@R13]\] reported that an OPM was observed in approximately 8% of advanced GC patients and 32% of early GC patients. Our previous study also showed that OPM was observed in 25% of GC patients \[[@R14]\]. In the present study, the incidence of OPM was 21.5%. The rate was especially high for antecedent and synchronous OPMs, which was probably because of the high proportion of elderly patients in our study.

In these situations, a relationship between OPMs and SMGC is currently being examined. Ojima *et al.* \[[@R5]\] reported that the presence of SMGC is a risk factor of synchronous colorectal cancer, while Kim *et al.* \[[@R6]\] reported SMGC as a predictive factor for future metachronous OPMs. Taken together, these studies suggest the presence of a common oncological or epidemiological factor that causes both MGC and OPMs. Miyoshi *et al.* \[[@R15]\] reported that microsatellite instability due to mutations of mismatch repair genes plays an important role in the development of MGC. Such genetic disorders have been demonstrated to be associated with the development of colorectal cancer, as well as other cancers, such as esophagus, thyroid, and prostate cancers, among others \[[@R16]--[@R20]\]. A genetic disorder, like a mismatch repair gene mutation, may be a common factor underlying the development of MGC and OPMs. The present study demonstrated that the presence of SMGC is a risk factor for the occurrence of OPMs postoperatively, as well as preoperatively. Several OPMs, including thyroid, esophagus, and colorectal cancers, were noted significantly more frequently in SMGC patients, both preoperatively and postoperatively, compared to in non-SMGC patients. Therefore, SMGC patients should be carefully assessed for the presence of these cancers, and gastrointestinal endoscopists, gastroenterologist, and surgeons should keep the relationship between SMGC and OPMs in mind.

The major determinant of prognosis in GC patients is the cancer stage, rather than the lesion number \[[@R1]\]. Our results showed that there were no differences in OS or DSS between the patients with or without SMGC. On the other hand, the presence of a preoperative OPM was an independent prognostic factor for OS. Our previous study also showed that GC patients with synchronous OPMs had a worse outcome after surgery than those without it \[[@R14]\]. Furthermore, Kim *et al.* \[[@R6]\] regarded that the presence of synchronous and metachronous OPMs negatively affected the clinical outcome of GC survivors. Our results suggest that OPMs may be associated with an increased risk of death. To improve the outcomes of GC patients, clinicians should make particular efforts to detect OPMs in patients with SMGC. It is important to consider the possibility of OPMs, especially in the organs where OPMs frequently occur. Routine esophagogastroduodenoscopy and colonoscopy are useful for detecting esophageal and colorectal cancers, respectively. However, the detection of cancers such as prostate and thyroid cancers is associated with a number of problems, including risks of overdiagnosis and overtreatment \[[@R21], [@R22]\]. Establishment of a standardized screening method for the detection of OPMs could contribute to improved survival in SMGC patients.

Our study has some limitations. First, our data included no information regarding the patients' familial history, staging of OPMs, and *Helicobacter pylori* infection status. *Helicobacter pylori* cause chronic gastritis, leading to cancer in the stomach \[[@R23]\], and might contribute to the incidence of MGC. Second, the follow-up period was not enough to detect all future GCs or OPMs.

In conclusion, because patients with preoperative OPMs have a high risk of SMGC, careful preoperative examination is recommended to improve the patients' prognosis.

MATERIALS AND METHODS {#s4}
=====================

SMGC definition and screening {#s4_1}
-----------------------------

SMGC was assessed by pathologic examination using the resected stomach samples, and the results were compared with the preoperative esophagogastroduodenoscopy findings. Multiplicity of GC was determined by the criteria of Moertel *et al.* \[[@R24]\], as follows: (1) two or more GCs must be pathologically proven to be malignant, (2) all lesions must be separated macroscopically by an area of normal gastric wall, and (3) the possibility that one of the lesions represents local extension of a metastatic tumor must be ruled out beyond reasonable doubt. Synchronicity of MGC was defined according to the criteria of Warren and Gates \[[@R25]\]. When two primary cancers were detected within 1 year, they were considered synchronous. When two primary cancers were detected more than 1 year apart, they were considered metachronous. The pathological features of the MGC were defined by main lesion, which is more advanced lesion and to be larger lesion if the depth of invasion was same.

OPM definition and screening {#s4_2}
----------------------------

Multiple primary cancers arising from other organs were also defined according to the criteria of Warren and Gates \[[@R25]\]. Metachronous multiple primary malignancies included antecedent malignancies before surgery for GC and subsequent malignancies after surgery for GC. In order to identify preoperative risk factors for MGC, we classified the OPMs into two groups: a preoperative group including antecedent and synchronous OPMs, and a postoperative group including subsequent OPMs.

The histopathologic findings of GC were obtained using the resected specimens. The clinicopathologic features of GC were described according to the TNM classification (7th edition).

Before surgery for GC, we performed total colonoscopy when patients were able to consume food. When colonoscopy could not be performed preoperatively, we performed it within 1 year after surgery. Furthermore, we performed whole-body computed tomography in order to detect OPMs. When malignancies were suspected in other organs, we added several examinations specific to the suspicious organs. After gastrectomy, the GC patients were followed in the outpatient clinic of each hospital not only to check for recurrence and metastasis of GC, but also to detect OPMs, by esophagogastroduodenoscopy, colonoscopy, and whole-body computed tomography. Furthermore, when the patients complained of symptoms other than those in the abdomen, we consulted clinical specialists.

Statistical analysis {#s4_3}
--------------------

Data are shown as the prevalence (%) or mean values. Continuous variables were compared using the Mann-Whitney test, and categorical variables were compared using the Chi-square test or Fisher's exact test, depending on their distribution. Multivariate analysis of independent risk factors was carried out by multiple logistic regression tests, and prognostic factors were analyzed by Cox's proportional hazard models. The survival rates after gastrectomy were calculated by the Kaplan-Meier method. The data were analyzed using IBM SPSS 22.0 (IBM Japan, Tokyo, Japan). For all analyses, *P* \< 0.05 was considered significant. Missing data were accounted for using a list-wise deletion approach.

**Author contributions**

Conception and design: Daisuke Takeuchi, Naohiko Koide; Administrative support: Shinichi Miyagawa; Collection and assembly of data: Daisuke Takeuchi, Akira Suzuki, Fumiaki Shimizu, and Naohiko Koide; Data analysis and interpretation: Daisuke Takeuchi, Naohiko Koide, Yusuke Miyagawa, and Shinichi Miyagawa; Manuscript writing: All authors.

We wish to thank the help in the study given by Prof. Shinichi Miyagawa.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

CI

:   confidence interval

DSS

:   disease-specific survival

GC

:   gastric cancer

HR

:   hazard ratio

MGC

:   multiple gastric cancers

OPM

:   other primary malignancy

OS

:   overall survival

SMGC

:   synchronous multiple gastric cancers
